asthma. Leukotriene (LT) C 4 , LTD 4 , and LTE 4 act on two G-protein-coupled receptors, CysLT1 and CysLT2 (1) (2) (3) (4) (5) . Asthmatic patients show increased production of cysLTs (6 -9) , mainly by eosinophils and mast cells (10) . CysLT1 shares 38% homology with CysLT2 and has been shown to promote bronchoconstriction and mucus secretion in response to cysLTs (11) (12) (13) . Selective antagonists for CysLT1 are in clinical use for the treatment of asthma. Conversely, the function of the CysLT2 receptor is, as yet, poorly defined.
Various reports have suggested a role for CysLT2 in a number of pathologies. The CysLT2 gene is localized on chromosome 13q14, a region linked to atopic asthma (3, 14) . Interestingly, a coding polymorphism in the CysLT2 receptor, which decreases responsiveness to LTD 4 , has been associated with resistance to asthma (15) . Furthermore, another report established an association of a CysLT2 variant with atopy in the Tristan da Cunha population (16) . An implication of this receptor in vascular permeability and bleomycin-induced pulmonary fibrosis has been suggested, using cyslt2 receptor-null mice (17) . Lotzer and colleagues (18) proposed an involvement of the CysLT2 receptor in inflammation and atherogenesis. In this regard, Qiu and colleagues (19) recently demonstrated the upregulation of CysLT2 receptor expression in carotid plaques of mice susceptible to atherosclerosis (ApoE Ϫ/Ϫ ). In humans, distribution of CysLT2 mRNA shows a high expression in peripheral blood leukocytes, adrenals, heart, brain, lymph nodes, and spleen (3, 4) . In situ hybridization indicates the expression of the CysLT2 receptor in the human lung, specifically in interstitial macrophages (3) . Moreover, expression of CysLT2 has been detected on eosinophils, mast cells, and mononuclear cells in the upper airways of seasonal allergic rhinitis patients (20) . Affinity of cysLTs for the CysLT2 receptor is LTC 4 ϭ LTD 4 Ͼ LTE 4 , as demonstrated by binding studies (3, 4) and cell populations that express CysLT1 usually coexpress CysLT2. No selective CysLT2 antagonist is available, however, at this time, making this receptor more difficult to study.
Inflammation is characterized by cellular infiltration, orchestrated by a cytokine/chemokine network. IL-8 (or CXCL8) is an important member of the chemokine superfamily, which plays a major role in the recruitment and activation of polymorphonuclear cells, thus promoting inflammation (21) . Several pathologies, including severe asthma and chronic obstructive pulmonary disease, are associated with elevated levels of IL-8 (22) (23) (24) . Regulation of IL-8 expression usually occurs at the transcriptional level. Its promoter region is well characterized and contains NF-B, AP-1, and NF-IL-6 transcription sites (25) . NF-B is involved in the expression of several genes controlling the immune and inflammatory responses (26) . NF-B complexes are dimer combinations of Rel family members composed of NF-B1(p50), NF-B2(p52), RelA(p65), and/or c-Rel (27, 28) . Activator Protein 1 (AP-1) is also a dimeric transcription factor, composed of the JUN (c-Jun, JunB, and JunD) and FOS (c-Fos, FosB, Fra1, and Fra-2) families, which regulate the expression of many genes, including IL-8, c-Jun (29) , and COX-2 (30) . On the other hand, nuclear factor IL-6 (NF-IL-6) also named CCAAT enhancer-binding protein (C/EBP), is usually characterized as a cofactor, cooperating with other transcription factors such as NF-B (31) (32) (33) .
We hypothesized that LTC 4 could transcriptionally up-regulate IL-8 and MCP-1 expression via the CysLT2 receptor. Furthermore, we investigated the signaling events following LTC 4 stimulation, in the context of IL-8 transcription. Human umbilical vein endothelial cells (HUVEC) at first passage as well as HEK-293 cells stably transfected with CysLT2 were used. Most of the studies that were performed with transfected HEK-293 cells could not have been done with early passage endothelial cells and thus the best surrogate cell model was used. Here, we provide the first evidence that the human CysLT2, in response to LTC 4 , activates specific PKC isozymes, as well as the NF-B and AP-1 transcription factors, and that this activation results in chemokine up-regulation. 4 and LTD 4 were purchased from Cayman Chemical (Ann Arbor, MI). GF109203X and rottlerin were obtained from Biomol Research Laboratory (Plymouth Meeting, PA), and dimethyl sulfoxide (Me 2 SO) from Fischer Scientific. Specific antibodies against p-IB␣ Ser-32/36(9246S), p-p65 Ser-536(3031S), and IB␣ (9242) were from Cell Signaling Technology (Beverly, MA) and p65 (sc-8008X), p65 (sc-372), p50 (sc-7178X), p52(sc-298X), c-Rel (sc-70X), c-Jun (sc-1694X), c-Fos (sc-52X), JunD (sc-74X), JunB (sc-46X), FosB (sc-48X), CREB1 (sc-240X), and CREB2 (sc-200X) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Aprotinin, 4-(2 aminoethyl)benzenesulfonyl fluoride, leupeptin, NaF, soybean trypsin inhibitor, and Na 3 VO 4 were from Sigma; Geneticin (G-418 Sulfate) (Invitrogen Canada Inc.) and FuGENE6 were purchased from Roche.
EXPERIMENTAL PROCEDURES

Materials-LTC
Plasmids-The plasmid encoding for IB␣ mutated at serines 32 and 36 was generously provided by Dr. Christian Jobin (University of North Carolina, Chapel Hill, NC). pCMVintron-cmycCysLT2R encoding for Myc-labeled human CysLT2 receptor and geneticin resistance, stabilized by a 5Ј ␤-globin intron and under the control of a CMV promoter, was constructed in our laboratory. The human IL-8 promoter luciferase constructs IL-8 WT,
IL-8-⌬AP-1, IL-8-⌬NF-B, and IL-8-⌬NF-IL-6
were generously provided by Dr. Allan R. Brasier from the University of Texas Medical Branch (34) . PKC dominant negative (dn) constructs (PKC␤II, PKC␦, PKC⑀, and PKC) were a kind gift from Drs. Gilles Dupuis and Jean-Guy Lehoux (35) from the Université de Sherbrooke; they were shown to be capable of effectively inhibiting selective PKC activities (36) .
Cells-Human embryonic kidney (HEK)-293 cells (American Type Culture Collection (ATCC), Rockville, MD) were cultured in Dulbecco's modified Eagle's medium with glucose (Invitrogen), supplemented with 10% fetal bovine serum (Sigma), and gentamicin sulfate (40 g/ml). Transient transfections were carried out with FuGENE 6, and experiments were performed 48 h post-transfection.
HEK-293 Stably Expressing CysLT2-HEK-293 cells grown at 50% confluence in 60-mm Petri dishes were stably transfected with 4 g of pCMVintron-cmyc-CysLT2R using 10 l of FuGENE 6. Forty-eight h following transfections, geneticin was added at a final concentration of 800 g/ml. Cells were then cultured for 2 weeks in medium containing geneticin and isolated for clonal selection. Cell clones were analyzed for Myc expression by FACScan flow cytometer (BD Bioscience). Positive clones were maintained in 800 g/ml geneticin and referred to as 293LT2. Untransfected or empty vector-transfected HEK293 cells expressed neither CysLT1 nor CysLT2 receptors.
HUVEC-Umbilical cords were obtained after uneventful deliveries, following informed consent from the mother. HUVEC were freshly isolated from umbilical veins by collagenase type V digestion as previously described (37) . Cells were cultured in Iscove's medium supplemented with fetal bovine serum (20%), endothelial cell grow supplement (VWR, Ville Mont-Royal, QC, Canada), and antibiotics. Experiments were performed with cell cultures at the first passage.
Northern Blot Analysis-Total cellular RNA was extracted using TriPure according to the manufacturer's instructions (Roche Diagnostics), 15 g of total RNA was separated by electrophoresis on 1% agarose and transferred onto a Hybond N ϩ (Amersham Biosciences) membrane. Human IL-8 cDNA probe (0.5-kb EcoRI fragment) and human MCP-1 cDNA probe were obtained from the ATCC. 28 S or 18 S were used as internal controls. The probes were labeled with a Ready-to-Go DNA Labeling Beads (dCTP) (Amersham Biosciences) using [␣- 32 P]dCTP (specific activity 3000 Ci/mmol; Amersham Biosciences). Membranes were prehybridized for 4 h in a mixture containing 120 mM Tris (pH 7.4), 600 mM NaCl, 8 mM EDTA (pH 8), 0.1% sodium pyrophosphate, 0.2% SDS, and 100 g/ml heparin; hybridization was performed overnight at 71 (IL-8) or 68°C (MCP-1) in the same mixture in which the concentration of heparin was increased to 625 g/ml and dextran sulfate at 10% was added. The membranes were then washed once at room temperature for 20 min in 2ϫ SSC (1ϫ SSC: 0.15 M NaCl, 0.15 M sodium citrate (pH 7)) and once with 0.1ϫ SSC. The membranes were exposed to Hyperfilm MP (Amersham Biosciences) with intensifying screens at Ϫ80°C.
Reverse Transcription and Quantitative PCR-For reverse transcription, 1 g of total RNA was mixed with 0.5 g of dT oligos (Amersham Biosciences) and 0.5 mM dNTPs (Roche) in Moloney murine leukemia virus reverse transcription buffer and incubated at 65°C for 5 min. Ten mM dithiothreitol (Invitrogen) and 200 units of Moloney murine leukemia virus reverse transcriptase (Promega, Madison, WI) were then added and tubes were incubated at 42°C for 50 min, followed by a 70°C incubation for 15 min.
For quantitative PCR analysis, 1 l of reverse transcription product was mixed with 5 M forward primer, 5 M reverse primer, 0.5 units of recombinant Taq polymerase (Amersham Biosciences), 0.25 mM dNTP, 1.25 mM MgCl 2 , and 1:30000 SYBR Green (Molecular Probes) final dilution in supplied Taq buffer, in a final volume of 20 l. PCR was started with a 3-min hold step at 95°C, followed by 50 times repeat of the cycling step: 15 s at 95°C, 20 s at 58°C, and 20 s at 73°C (acquiring on Fam/Syb) and ended by a melt step rising from 72 to 95°C. Experiments were performed on RotorGene 3000 PCR machine from Corbett Research (Montreal Biotech Inc., Kirkland, QC, Canada) using Rotor-gene 6 (build 21) software. Data analysis was performed according to the 2 Ϫ⌬⌬CT method as previously described (38, 39) . The primer sequences were: GAPDH forward, 5Ј-GATGACATCAAGAAGGTGGTGAA-3Ј; GAPDH reverse, 5Ј-GTGTTACTCCTTGGAGGCCA-TGT-3Ј; IL-8 forward, 5Ј-TCTGCAGCTCTGTGTGAAGG-3Ј; IL-8 reverse, 5Ј-AGTTTTCCTTGGGGTCCAGA-3Ј.
Western Blot Analysis-293LT2 cells in 6-well plates were incubated in medium without serum for 24 h, stimulated with LTC 4 (20 nM) for the indicated times, and lysed in buffer: 50 mM Tris (pH 7.5), 1 mM EGTA, 150 mM NaCl, 1 mM NaF, 1 mM Na 3 VO 4 , 1% Triton X-100, 0.25% sodium deoxycholate, 1 g/ml leupeptin, 2 g/ml aprotinin, 10 g/ml soybean trypsin inhibitor, for 30 min on ice. Total lysates were separated on 10% SDS-PAGE, and transferred to Trans-Blot nitrocellulose membrane (Bio-Rad). Membranes were blocked with Tris-buffered saline with 5% dry milk for 1 h and incubated with specific antibodies in Tris-buffered saline, 0.1% Tween, and 5% dry milk overnight at 4°C. After washing and incubation with secondary antibodies, an ECL detection system was used for protein detection (Amersham Biosciences). Membranes were stripped by incubation in 62.5 mM Tris-HCl (pH 6.8), 2% SDS, and 10 mM 2-mercaptoethanol for 30 min at 50°C. After washing, membranes were reprobed with the appropriate antibodies and developed as described above.
Electrophoretic Mobility Shift Assay (EMSA)-293LT2 cells were cultured in 6-well plates until nearly confluent; cells were starved overnight. Cells were then stimulated with LTC 4 , LTD 4 , or EtOH for the indicated times and incubations were stopped by adding an equal volume of ice-cold phosphate-buffered saline containing 10 mM NaF and 1 mM Na 3 VO 4 . Cells were collected by gentle scraping and centrifuged at 1000 ϫ g for 3 min at 4°C. The resulting cell pellets were resuspended in icecold lysis buffer (10 mM HEPES (pH 7.90), 10 mM NaCl, 1.5 mM MgCl 2 , 1 mM EDTA, 0.5 mM EGTA, and 0.5 mM dithiothreitol) containing an antiprotease mixture (0.5 mM diisopropyl fluorophosphate, 0.5 mM 4-(2 aminoethyl)benzenesulfonyl fluoride, 1 mM phenylmethylsulfonyl fluoride, and 10 g/ml each of aprotinin, leupeptin, and pepstatin A, final concentrations). After a 10-min incubation on ice, an equal volume of lysis buffer containing the antiprotease mixture as well as 0.2% Nonidet P-40 was added (to yield a final concentration of 0.1% Nonidet P-40). Samples were immediately vortex mixed for 15 s before centrifugation at 1200 ϫ g (5 min at 4°C). The resulting nuclear pellets were washed once with lysis buffer containing the antiprotease mixture before being resuspended in ice-cold nuclear extraction buffer (20 mM HEPES (pH 7.90), 400 mM NaCl, 1.5 mM MgCl 2 , 1 mM EDTA, 0.5 mM dithiothreitol, and 10% (v/v) glycerol) containing the antiprotease mixture. After a 20-min incubation on ice (with frequent mixing), samples were spun (15,000 ϫ g for 15 min at 4°C), and supernatants (the nuclear extracts) were snap-frozen in liquid nitrogen and stored at Ϫ80°C. Extracts were routinely processed for protein content determination. The sequences of the sense strands of the oligonucleotides used for EMSA were as follows: 5Ј-AGTTGAGGG-GACTTTCCCAGGC-3Ј (NF-B), 5Ј-CGCTTGATGAGT-CAGCCGGAA-3Ј (AP-1) from Promega (Madison, WI)) and 5Ј-AGTTGAGGCGACTTTCCCAGGC-3Ј (NF-B mutant) 5Ј-CGCTTGATGACTTGGCCGGAA-3Ј (AP-1 mutant) from Santa Cruz Biotechnology. For supershift experiments, binding reactions were conducted in the presence of specific antisera to individual c-Jun, JunB, JunD, c-Fos, FosB, CREB1, CREB2 or p65, p50, p52, c-Rel proteins (30 min at 4°C), before the addition of ␥-32 P-labeled probes. Samples were electrophoresed on 6% acrylamide gels at 4°C in 0.5ϫ TBE; dried gels were then exposed to Hyperfilm MP (Amersham Biosciences) with intensifying screens at Ϫ80°C.
Luciferase Assays-293LT2 cells were plated in 12-well tissue culture plates 24 h before transfection with 0.5 g of plasmid DNA per well, using 1.5 l of FuGENE 6 transfection reagent (Roche) according to the manufacturer's instructions. The day after transfection, cells were serum-starved overnight before stimulation with LTC 4 (20 nM) or EtOH for 6 h. Cell lysates were assayed for luciferase activity as previously described (40) .
Enzyme-linked Immunosorbent Assay-293LT2 cells were cultured in 12-well culture plates and serum-starved overnight before stimulation with LTC 4 for the indicated times. Cell-free culture supernatants were carefully collected, snap-frozen in liquid nitogen, and stored at Ϫ80°C. IL-8 concentrations were determined using the Opt-EIA Human IL-8 enzyme-linked immunosorbent assay kit (BD Pharmingen).
Statistical Analyses-Where mentioned, statistical significance was assessed using the Student's t test for paired data (one-tailed) or analysis of variance, as required, using PRISM4 software (GraphPad Software Inc., San Diego, CA). Differences were considered significant at p Յ 0.05.
RESULTS
LTC 4 Regulates IL-8 and MCP-1 Expression in 293LT2 Cells-
Because several primary cell types express both CysLT2 and CysLT1 receptors and because of a lack of selective CysLT2 antagonists, we generated a cell line that stably expresses only the CysLT2 receptor, referred to as 293LT2 cells, as described under "Experimental Procedures." This provided a useful tool to selectively study the signaling pathways downstream of the CysLT2 receptor. Many of the studies that were performed with the 293LT2 cells could not have been done with early passage primary cells and thus the best surrogate cell model was used. (Fig. 1B) . Empty vectortransfected HEK293 cells showed no response to LTC 4 stimulation (data not shown).
LTC 4 and LTD 4 Induce IL-8 Promoter Activity in a Concentration-dependent Manner-To determine whether LTC 4 -induced IL-8 gene expression occurs at the transcriptional level, 293LT2 cells were transfected with a luciferase reporter gene driven by the IL-8 promoter and the promoter activity was measured following stimulation with LTC 4 or LTD 4 . As shown in Fig. 2A , LTC 4 strongly up-regulated IL-8 transactivation in a concentration-dependent manner, with a maximal effect at 200 nM LTC 4 for 6 h. LTD 4 also induced IL-8 transactivation, with 200 nM giving the highest induction ( Fig. 2A) . Interestingly, LTC 4 was more potent than LTD 4 and induced equivalent IL-8 promoter activity at 10-fold lower concentrations. IL-8 promoter activity in response to cysLT stimulation was not induced in untransfected HEK293 cells (data not shown).
LTC 4 -induced IL-8 Promoter Activity Is Dependent on NF-B, AP-1, and NF-IL-6
Sites-To determine the transcription factor binding sites involved in the induction of IL-8 transactivation in response to LTC 4 , site-specific mutants of the 5Ј-flanking region of the IL-8 gene were used (34) . As shown in Fig. 2B , the NF-B site mutation reduced drastically (by 90%) the IL-8 promoter activity induced by LTC 4 . Mutation within the AP-1 site resulted in a 75% reduction of the LTC 4 -induced IL-8 transactivation, whereas the NF-IL-6 site mutation caused only a 40% reduction.
LTC 4 Activates Different NF-B Pathway Elements-Because we observed the involvement of NF-B, we addressed the elements of this pathway that could be activated by LTC 4 . Fig. 3A illustrates the induction of IB␣ phosphorylation following LTC 4 stimulation with a maximal induction after 15 min. As also shown in Fig. 3A (top panel) , LTC 4 induced a time-dependent phosphorylation of the p65 NF-B subunit, on serine 536. To assess whether IB␣ activation was required for LTC 4 -induced IL-8 promoter transactivation, 293LT2 cells were cotransfected with a dominant-negative form of IB␣ and the IL-8-luc reporter construct and then stimulated with LTC 4 . As illustrated in Fig. 3B , overexpression of dominant-negative IB␣ inhibited IL-8 promoter activity by 90% in response to LTC 4 . LTC 4 Increases NF-B DNA Binding Activity-Based on the above results, we investigated whether LTC 4 could up-regulate NF-B DNA binding. Fig. 4A illustrates the kinetics of LTC 4 -induced NF-B DNA binding, indicating an induction that could be seen within 15 min of stimulation. As seen above ( Fig.  2A) , LTC 4 was also a better agonist than LTD 4 in inducing NF-B binding (Fig. 4A) . Analysis of the DNA binding complex following LTC 4 stimulation was performed using specific antibodies. Supershift experiments indicated that the NF-B binding complex contained p50 and p65 subunits (Fig. 4B) .
LTC 4 Stimulates the DNA Binding of AP-1-We also investigated whether LTC 4 stimulation of the 293LT2 cells could modulate AP-1 DNA binding activity. As shown in Fig. 5A , 293LT2 cells exposed to 20 nM LTC 4 for the indicated periods of time showed a time-dependent induction of AP-1 DNA binding activity, which was evident at 60 min. Fig. 5A also indicates a stronger induction of AP-1 DNA binding activity by LTC 4 than by LTD 4 . Supershift experiments showed that the AP-1 binding complex was composed of c-JUN and c-FOS proteins (Fig. 5B) . 4 , even at 20 M SP600125. The efficacy of the JNK inhibitor was confirmed, however, by its capacity to inhibit JNK phosphorylation induced by LTC 4 (Fig. 6B) . SP600125 was also unable to prevent LTC 4 -induced IL-8 transactivation, as shown in Fig. 6C . Interestingly, LTC 4 thus appears to be an inducer of JNK activation, but this enzyme is not involved in LTC 4 -induced IL-8 expression.
Protein Kinase C Is Important in CysLT2-mediated IL-8 Transactivation-Because JNK was not involved in LTC 4 induced IL-8 expression, we investigated whether PKC could play a role in AP-1-dependent IL-8 transactivation. HEK293 cells are known to express endogenous PKC␤I, PKC␤II, PKC␦, and to a lesser extent PKC⑀ and PKC isozymes (41) .
Pretreatment of 293LT2 cells with the broad-spectrum PKC inhibitor, GF109203X, or the PKC␦-specific inhibitor, rottlerin, significantly abrogated LTC 4 -induced IL-8 promoter activation (Fig. 7A) . LTC 4 was also found to induce PKC␦ phosphorylation in a timedependent manner (Fig. 7B) . Furthermore, because of the potential risk for erroneous interpretations when using biochemical inhibitors, we resorted to dominant negative forms of PKC isoforms. As illustrated in Fig. 7C , specific dominant-negative constructs for PKC␦, PKC⑀, and to a lesser extent, PKC also reduced LTC 4 -induced IL-8 transactivation, thus suggesting the implication of these PKC isozymes in LTC 4 -induced IL-8 gene transcription. In contrast, the dominant-negative PKC␤II construct only had a minor impact on LTC 4 -induced IL-8 transcription (Fig. 7C) .
PKC␦ Is Required for LTC 4 -induced AP-1 Pathway Activation-
Interestingly, LTC 4 -induced phosphorylation of c-JUN was inhibited by rottlerin (Fig. 8A) , suggesting that PKC␦ was required for c-JUN activation. This was also reflected in LTC 4 -induced AP-1 DNA binding (Fig. 8B) , with inhibition with rottlerin and GF109203X, but not with the JNK inhibitor SP600125. Furthermore, GF109203X, but not rottlerin prevented LTC 4 -induced phosphorylation of JNK (Fig. 8C) . Finally, when 293LT2 cells were transfected with dnPKC isozymes, only PKC␦ was capable of inhibiting LTC 4 -induced AP-1 DNA binding (Fig. 8D) . We were unable, however, to prevent c-Jun phosphorylation using any of the dnPKC isozymes (data not illustrated).
LTC 4 -mediated NF-B Activation Involves PKC⑀-LTC 4 was found to phosphorylate p65 in a CysLT2-dependent and a PKCdependent manner, but without inhibition by rottlerin, suggesting that a PKC isozyme other than PKC␦ would be involved (Fig. 9A) . This was also observed in LTC 4 -induced NF-B DNA binding (Fig. 9B) . However, 293LT2 cells transfected with dominant-negative forms of PKC⑀, PKC␦, or PKC revealed that LTC 4 -induced phosphorylation of p65 was only dependent on PKC⑀ (Fig. 9C) . In contrast, neither of the dominant-negative isoforms of PKC inhibited LTC 4 -induced NF-B DNA binding (Fig. 9D) . 
LTC 4 Induces IL-8 Gene Expression in Human Endothelial
Cells-HUVEC readily express the CysLT2 receptor, with very low expression of CysLT1. The effects of cysLTs on HUVEC have been shown to be the consequence of CysLT2 activation, because specific CysLT1 antagonists do not prevent cysLT stimulation (18) . As shown in Fig. 10A , LTC 4 induced a timedependent expression of IL-8 mRNA in HUVEC, with maximal effects observed following 2 h of LTC 4 stimulation. This was not prevented by pretreatment with the CysLT1 receptor antagonist montelukast (data not illustrated). Furthermore, as shown in Fig. 10B , pretreatment of HUVEC with the broadspectrum PKC inhibitor, GF109203X, completely abrogated LTC 4 -induced IL-8 transcription.
DISCUSSION
Cysteinyl-leukotrienes are lipid mediators with a proinflammatory profile and have been implicated in the pathogenesis of several types of inflammation. The role of the CysLT1 receptor is being extensively investigated and characterized. Conversely, the mechanisms responsible for inflammation driven by the CysLT2 receptor have not been reported as yet. This may be due, in part, to the fact that many cell types express both CysLT2 and CysLT1 receptors and to the lack of selective antagonists for CysLT2.
In the present study, we demonstrate that LTC 4 , acting through the CysLT2 receptor, can directly activate the production of chemokines IL-8 and MCP-1. These are potent mediators of inflammation and play key roles in the recruitment and activation of several immune cell populations. High levels of IL-8 have been reported in several pathologies, including severe asthma and chronic obstructive lung disease (22) (23) (24) . Our results indicate that LTC 4 induces a time-dependent expression of IL-8 at both the mRNA and protein levels and also induces a concentration-dependent transactivation of the IL-8 promoter. Interestingly, although LTC 4 and LTD 4 have equal binding affinity for CysLT2 (3, 4), we found LTC 4 to be ϳ10-fold more potent than LTD 4 for CysLT2 receptor activation at low nanomolar concentrations. This may be the result of different conformational changes induced in the CysLT2 receptor by the two structurally different ligands, despite their equivalent affinities. A major aim of this work was to investigate the signaling pathways that could be activated via the CysLT2 receptor. Many of the assays were performed with transfected HEK-293 cells stably expressing CysLT2, because they could not have been done with first passage HUVEC and thus the best surrogate cell model was used.
NF-B is a powerful transcription factor involved in the activation of many inflammatory genes, including the IL-8 gene, following stimulation by LPS or proinflammatory cytokines such as TNF-␣ and IL-1␤ (42) . NF-B has also been reported to be activated by G-protein-coupled receptor signaling (43, 44) . Our data show that a mutation in the NF-B site within the IL-8 reporter construct reduced the IL-8 promoter activity induced by LTC 4 in 293LT2 cells by 90%, indicating a major role for the NF-B transcription factor in CysLT2 signaling.
In unstimulated cells, the NF-B complex is maintained in an inactive form by the binding of p65 to its inhibitory factor IB␣ (45) . Following activation, IKK phophorylates IB␣ on serines 32 and 36, leading to rapid polyubiquitination and degradation of IB␣ in the proteasome (46, 47) . Free p65 subunits can then translocate to the nucleus and activate gene transcription. Our results demonstrate that LTC 4 can induce the phosphorylation of IB␣, in a time-dependent manner, with a maximal induction at 15 min. Furthermore, LTC 4 is also able to stimulate the phosphorylation of p65 at serine 536. Our data show as well that expression of a dominant-negative form of IB␣ in 293LT2 cells abrogates by 90% LTC 4 -induced IL-8 promoter transactivation, indicating a major role for IB␣ in CysLT2 receptor signaling. NF-B is a homo-or heterodimer composed of different combinations of Rel family members. We determined by supershift assays that LTC 4 induced the formation of a functional p50⅐p65 NF-B complex.
Interestingly, AP-1 was also implicated in CysLT2 receptor signaling. AP-1 responsive elements are part of many gene promoters, including IL-8 (34), COX-2 (30), and c-Jun (29) . We initially demonstrated that an AP-1 site mutation decreased by 75% the IL-8 promoter activity stimulated by LTC 4 . Next we showed that LTC 4 strongly induced DNA binding of AP-1. Furthermore, our results provided the first evidence that LTC 4 induces the formation of a functional c-JUN⅐c-FOS complex. The AP-1 complex can be regulated by a post-translational phosphorylation, which can influence the stability of its members, its transactivating potential, and its DNA-binding capacity (48) . Here we showed a strong phosphorylation of c-JUN, following 60 min of LTC 4 stimulation. Interestingly, although LTC 4 stimulation also resulted in phosphorylation of JNK, which is usually responsible for c-JUN phosphorylation, inhibition of JNK activity neither affected c-Jun phosphorylation nor LTC 4 -induced IL-8 promoter transactivation. With the use of dominant-negative PKC isozymes, it appears that AP-1 activation and DNA binding are mediated through PKC␦, independently of JNK activation. At this time, we have no explanation for the apparent lack of involvement of JNK in LTC 4 -induced c-Jun phosphorylation and AP-1 DNA binding. Results from our laboratory, however, indicate that phosphorylation of other members of the mitogen-activated protein kinase family, namely p38 and Erk, also occurs in response to LTC 4 despite their lack of implication in IL-8 transactivation. 3 Interestingly, SP600125 was capable of inhibiting LTC 4 -induced JNK phosphorylation, possibly by inhibiting its autophosphorylation.
We studied whether PKC could be an upstream element of the CysLT2 signaling leading to IL-8 transactivation. PKCs are serine/threonine kinases that play a role in several signaling pathways implicated in cell proliferation, apoptosis, and gene activation (49, 50) . The PKC family is divided into three classes of isoenzymes, the conventional PKC isoforms ␣, ␤I, ␤II, and ␥ regulated by Ca 2ϩ and diacylglycerol, the novel PKC isoforms ␦, ⑀, , and dependent on diacylglycerol but not on Ca 2ϩ and the atypical PKC isoforms , , and , which are both Ca 2ϩ -and diacylglycerol-independent. Several reports indicate that PKC is an upstream effector of NF-B activating pathways leading to chemokine secretion (51, 52) . Studies by Thodeti and colleagues (53) indicate that LTD 4 can activate PKC␣, ␦, and ⑀, but not ␤II, in intestinal epithelial cells, a mechanism triggered by the CysLT1 receptor. Our results demonstrate an implication of PKCs in IL-8 transactivation, based on the use of dominantnegative isoforms of PKCs and biochemical inhibitors: GF109203X, a broad PKC inhibitor, and rottlerin, a reportedly selective PKC␦ inhibitor. We also found PKC␦ to be an upstream element of the AP-1 pathway, because both rottlerin and dnPKC␦ inhibited AP-1 DNA binding. Although rottlerin pretreatment could also abrogate c-Jun phosphorylation following LTC 4 stimulation, neither dnPKC␦, -⑀, nor -could. At this time, the kinase responsible for LTC 4 -induced c-Jun phosphorylation remains to be identified. Such a rottlerin-sensitive, but PKC␦-independent signaling pathway has recently been reported in B lymphocyte receptor signaling (54) .
Interestingly, neither rottlerin nor dnPKC␦ affected the NF-B pathway, in terms of p65 phosphorylation and NF-B DNA binding. Conversely, in other G-protein-coupled receptors signaling, PKC␦ was reported to mediate lysophosphatidic acid-and substance P-induced NF-B activation (51, 52) .
Upstream elements affecting the NF-B pathway following CysLT2 receptor stimulation appear to involve PKC⑀. Indeed GF109203X, but not rottlerin, was able to inhibit NF-B pathway activation by LTC 4 and dnPKC⑀ inhibited both p65 phosphorylation and IL-8 transactivation following LTC 4 stimulation. In this regard, a recent study indicated that PKC⑀ was required for formylmethionylleucylphenylalanine-induced activation of NF-B (55). Interestingly, neither PKC⑀, PKC␦, nor PKC significantly affected LTC 4 -induced NF-B DNA binding. It is known, however, that p65 phosphorylation is not essential for its translocation to the nucleus and its binding to DNA, but important for its enhanced transactivating effect (56, 57) .
We have also found that dnPKC partially prevented LTC 4 -induced IL-8 transactivation, but PKC appeared not to play a role in either AP-1 or NF-B activation following LTC 4 stimulation. Several reports, however, suggest that PKC may be involved in the activation of the NF-B pathway. For instance, overexpression of PKC in NIH-3T3 fibroblasts provoked a permanent translocation of active NF-B into the nucleus (58) and PKC has been shown to phosphorylate the p65 subunit and IKK␤ (59 -61) .
Finally, we demonstrated the induction of IL-8 transcripts by LTC 4 in primary HUVEC, which was not prevented by the CysLT1 antagonist montelukast, but was abrogated by PKC inhibition. Lotzer and colleagues (18) reported that HUVEC predominantly expressed a functional CysLT2 receptor, rather than CysLT1, as evidenced by a calcium flux in response to LTD 4 that was not blocked by CysLT1 antagonists. Moreover, HUVEC express high levels of CysLT2 mRNA, but very few transcripts of CysLT1 receptor (62) . During the preparation of this manuscript, Uzonyi and colleagues (63) reported that CysLT2 and protease-activated receptor 1 can activate early genes, including IL-8, in endothelial cells. Our results corroborate and extend these data. Indeed, the major findings of the present study are the definition of some of the signaling pathways induced by the CysLT2 receptor, which had not been reported as yet.
CysLT1 and CysLT2 receptors share similar types of G-protein signaling and could therefore use similar downstream signaling pathways. Indeed, we have recently shown that LTD 4 -induced CysLT1 activation can also lead to IL-8 production, but with a predominant involvement of AP-1 and no involvement of NF-IL-6 (40) .
In summary, we provide evidence for a major involvement of the PKC isozymes ␦ and ⑀ and transcription factors NF-B and AP-1 in CysLT2 receptor signaling that leads to chemokine gene activation. Fig. 11 summarizes the CysLT2 signaling cascade that we found in this study. Taken together, our data suggest the potential for the CysLT2 receptor to induce additional proinflammatory genes, via its capacity to activate NF-B and AP-1 transcription factors.
